PRESS RELEASE published on 09/29/2025 at 23:00, 4 months 8 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 4 months 8 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 5 months 10 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 5 months 10 days ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 6 months 21 days ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 6 months 21 days ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 6 months 22 days ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
BRIEF published on 07/03/2025 at 21:24, 7 months 4 days ago GenSight Biologics completes private placement of nearly €4 million Private Placement Common Shares Euronext Funding GenSight Biologics
PRESS RELEASE published on 07/03/2025 at 21:19, 7 months 4 days ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics closes EUR 3.9M private placement with issuance of ordinary shares, pre-funded warrants, investor warrants. Funds to repay convertible bonds. Maxim Group, LLC acted as placement agent Private Placement Ordinary Shares GenSight Biologics Maxim Group EUR 3.9M
BRIEF published on 07/01/2025 at 08:59, 7 months 6 days ago GenSight Biologics raises nearly €4 million in private placement Private Placement Investment GenSight Biologics Euronext Shares LUMEVOQ ®
Published on 02/07/2026 at 01:00, 1 day 7 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 9 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 10 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 17 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 19 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 11 hours 42 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 16 hours 7 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 16 hours 22 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 13 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 14 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 14 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 16 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 14 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
